免疫检查点抑制剂相关急性肾损伤的临床特征与结局:多中心研究
该多中心研究纳入138例免疫检查点抑制剂相关AKI患者及276例对照,发现基线eGFR低、使用质子泵抑制剂和联合免疫治疗是独立危险因素;从用药到AKI中位时间14周,活检者93%为肾小管间质性肾炎,86%用激素,完全、部分、未恢复分别占40%、45%、15%,未恢复与更高死亡率独立相关。
要点
- 基线eGFR低、质子泵抑制剂使用、联合免疫治疗独立增加ICI相关AKI风险。
- 活检者93%为肾小管间质性肾炎,86%接受激素治疗。
- 肾脏未恢复与更高死亡率独立相关,再挑战者23%复发。
核心结论
- ICI相关AKI多表现为肾小管间质性肾炎,肾脏未恢复与更高死亡率独立相关。
研究设计与样本
- 多中心研究纳入138例ICI相关AKI患者(血清肌酐较基线≥2倍升高或新透析依赖直接归因于ICI)及276例接受ICI但未发生AKI的对照。
主要发现
- 基线eGFR较低、使用质子泵抑制剂和联合ICI治疗分别与ICI相关AKI风险增加独立相关。
- 从ICI启动至AKI的中位时间14周(IQR 6-37周)。
- 多数患者为亚肾病范围蛋白尿,约半数有脓尿;43%发生肾外免疫相关不良事件,69%同时使用潜在致肾小管间质性肾炎药物。
- 60例活检者中93%以肾小管间质性肾炎为主要病变;86%接受激素治疗。
- 肾脏完全恢复、部分恢复、未恢复分别占40%、45%、15%;合并肾外免疫相关不良事件与更差肾脏预后相关,合并致肾小管间质性肾炎药物和激素治疗分别与更好肾脏预后相关。
关键数值与推荐
- ICI相关AKI定义为血清肌酐较基线≥2倍升高或新透析依赖直接归因于ICI。
临床怎么用
- 对ICI治疗患者应关注基线eGFR、质子泵抑制剂使用和联合治疗等风险因素。
- 发生ICI相关AKI时需评估肾小管间质性肾炎,多数患者接受激素治疗。
- 肾脏未恢复者死亡风险更高,再挑战需警惕复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite increasing recognition of the importance of immune checkpoint inhibitor-associated AKI, data on this complication of immunotherapy are sparse. METHODS: We conducted a multicenter study of 138 patients with immune checkpoint inhibitor-associated AKI, defined as a ≥2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI. RESULTS: Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently associated with an increased risk of immune checkpoint inhibitor-associated AKI. Median (interquartile range) time from immune checkpoint inhibitor initiation to AKI was 14 (6-37) weeks. Most patients had subnephrotic proteinuria, and approximately half had pyuria. Extrarenal immune-related adverse events occurred in 43% of patients; 69% were concurrently receiving a potential tubulointerstitial nephritis-causing medication. Tubulointerstitial nephritis was the dominant lesion in 93% of the 60 patients biopsied. Most patients (86%) were treated with steroids. Complete, partial, or no kidney recovery occurred in 40%, 45%, and 15% of patients, respectively. Concomitant extrarenal immune-related adverse events were associated with worse renal prognosis, whereas concomitant tubulointerstitial nephritis-causing medications and treatment with steroids were each associated with improved renal prognosis. Failure to achieve kidney recovery after immune checkpoint inhibitor-associated AKI was independently associated with higher mortality. Immune checkpoint inhibitor rechallenge occurred in 22% of patients, of whom 23% developed recurrent associated AKI. CONCLUSIONS: This multicenter study identifies insights into the risk factors, clinical features, histopathologic findings, and renal and overall outcomes in patients with immune checkpoint inhibitor-associated AKI.
引用
- Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020. PMID: 31896554. doi:10.1681/ASN.2019070676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。